{"title":"VIII International Workshop on Chronic Lymphocytic Leukaemia. 29-31 October 1999, Paris, France. Proceedings and abstracts.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21867279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-06-01DOI: 10.1007/s00282-000-0021-4
F Caligaris-Cappio
{"title":"Cellular interactions, immunodeficiency and autoimmunity in CLL.","authors":"F Caligaris-Cappio","doi":"10.1007/s00282-000-0021-4","DOIUrl":"https://doi.org/10.1007/s00282-000-0021-4","url":null,"abstract":"","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-000-0021-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21867283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-06-01DOI: 10.1007/s00282-000-0049-5
J L Binet
{"title":"Emerging therapies and future directions in CLL--monoclonal antibodies, vaccines and gene therapy.","authors":"J L Binet","doi":"10.1007/s00282-000-0049-5","DOIUrl":"https://doi.org/10.1007/s00282-000-0049-5","url":null,"abstract":"","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-000-0049-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21867288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-06-01DOI: 10.1007/s00282-000-0015-2
D Catovsky
{"title":"CLL variants and T-cell-related issues.","authors":"D Catovsky","doi":"10.1007/s00282-000-0015-2","DOIUrl":"https://doi.org/10.1007/s00282-000-0015-2","url":null,"abstract":"","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-000-0015-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21867282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2000-06-01DOI: 10.1007/s00282-000-0031-2
E Montserrat
{"title":"Current therapy for CLL.","authors":"E Montserrat","doi":"10.1007/s00282-000-0031-2","DOIUrl":"https://doi.org/10.1007/s00282-000-0031-2","url":null,"abstract":"","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2000-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-000-0031-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21867285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-11-01DOI: 10.1007/s00282-999-0191-7
F Bauduer, S Katsahian, Y Blanchard, B Oui, C Capdupuy, M Renoux
From January 1995 to June 1998, 136 new cases of non-Hodgkin lymphomas (NHLs) were seen in our center which serves all the French Basque Country (300000 inhabitants). The crude and standardized incidence rates were respectively 13.2 and 7.6 cases/100000/year. The distribution of histologic subtypes according to the REAL classification showed a good correlation with the previous published data. Eleven patients (8%) were HIV-positive and two (1.4%) were HCV carriers. Hence, in our region, contrary to Italy, there is no evidence of relationship between HCV and NHLs.
{"title":"Descriptive epidemiology of non-Hodgkin lymphomas in a southwestern French hematology center: absence of significant relationship with hepatitis C virus infection.","authors":"F Bauduer, S Katsahian, Y Blanchard, B Oui, C Capdupuy, M Renoux","doi":"10.1007/s00282-999-0191-7","DOIUrl":"https://doi.org/10.1007/s00282-999-0191-7","url":null,"abstract":"<p><p>From January 1995 to June 1998, 136 new cases of non-Hodgkin lymphomas (NHLs) were seen in our center which serves all the French Basque Country (300000 inhabitants). The crude and standardized incidence rates were respectively 13.2 and 7.6 cases/100000/year. The distribution of histologic subtypes according to the REAL classification showed a good correlation with the previous published data. Eleven patients (8%) were HIV-positive and two (1.4%) were HCV carriers. Hence, in our region, contrary to Italy, there is no evidence of relationship between HCV and NHLs.</p>","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1999-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-999-0191-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21505979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1999-11-01DOI: 10.1007/s00282-999-0217-1
S Diop, D Thiam, M Cisse, A O Toure-Fall, K Fall, L Diakhate
Despite the unicity of its genetic mutation, Sickle cell homozygosity presents different clinical features. Our objectives were to evaluate disease severity in Senegalese patients. Sixty (60) homozygous sickle cell patients were followed up monthly during one year and disease severity was assessed using the "severity index" (SI) which is resulting from epidemiologic, clinic and biological data. Mean age was 20.13, sex ratio was 0.87 and mean age of diagnosis was 9.8 years. 90% of patients presented vaso-occlusive crisis (2.53 per patient), 73.3% had infectious episodes (1.9 per patient), 69.3% had never been transfused and 25% of patients had presented chronic complications linked to anemia or ischemia. Mean hemoglobin value was 8.1 g/dl and mean Hb F was 8.2%. Low seric ferritin was found in 1.7% of patients. Benign form of homozygous sickle cell anemia (SI< or =6) was found in 48.3% of patients. Our data confirm the relative good tolerance of homozygous sickle cell disease in Senegal. The haplotype Senegal may play an important role but others host and environmental factors operate certainly because some severe cases were identified in our patients. The identification of all these factors might contribute to a better follow up of sickle cell disease.
{"title":"New results in clinical severity of homozygous sickle cell anemia, in Dakar, Senegal.","authors":"S Diop, D Thiam, M Cisse, A O Toure-Fall, K Fall, L Diakhate","doi":"10.1007/s00282-999-0217-1","DOIUrl":"https://doi.org/10.1007/s00282-999-0217-1","url":null,"abstract":"<p><p>Despite the unicity of its genetic mutation, Sickle cell homozygosity presents different clinical features. Our objectives were to evaluate disease severity in Senegalese patients. Sixty (60) homozygous sickle cell patients were followed up monthly during one year and disease severity was assessed using the \"severity index\" (SI) which is resulting from epidemiologic, clinic and biological data. Mean age was 20.13, sex ratio was 0.87 and mean age of diagnosis was 9.8 years. 90% of patients presented vaso-occlusive crisis (2.53 per patient), 73.3% had infectious episodes (1.9 per patient), 69.3% had never been transfused and 25% of patients had presented chronic complications linked to anemia or ischemia. Mean hemoglobin value was 8.1 g/dl and mean Hb F was 8.2%. Low seric ferritin was found in 1.7% of patients. Benign form of homozygous sickle cell anemia (SI< or =6) was found in 48.3% of patients. Our data confirm the relative good tolerance of homozygous sickle cell disease in Senegal. The haplotype Senegal may play an important role but others host and environmental factors operate certainly because some severe cases were identified in our patients. The identification of all these factors might contribute to a better follow up of sickle cell disease.</p>","PeriodicalId":73231,"journal":{"name":"Hematology and cell therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"1999-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00282-999-0217-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"21505984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号